Lumida
/AVIR
⌘K
Atea Pharmaceuticals Inc

Atea Pharmaceuticals Inc

AVIR
$5.31USD↑+2.51%+0.13 today

MARKET CAP

425.9M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$5 – $5

52W RANGE

$3
$6

AI Summary

Stalk
TrimMedium

In a Stage 3 distribution range, price remains below down-sloping EMAs and the 50 DMA, with rallies failing into resistance and volume contracting on advances. The 3-year uptrend anchors long-term polarity, but medium-term asymmetry favors sellers. Short-term timing offers no clear edge until rallies into the 9/21 EMA zone. Execution should focus on fading strength at these EMAs around the upper boundary of the trading range.

  • ↑Phase III C-BEYOND trial showed 93.9% SVR, non-inferior to standards.
  • ↑Cash position of $219.5M as of June 2026 funds R&D through 2027.
  • ↓Negative earnings yield and weak profitability signal financial distress.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Atea Pharmaceuticals, Inc. (NASDAQ: ATEA) is a biopharmaceutical company specializing in developing antiviral therapies for chronic hepatitis C (HCV) and hepatitis E (HEV). Atea’s strategy revolves around its lead candidates, bemnifosbuvir and ruzosvir (BEM/RZR), which aim to disrupt existing treatment paradigms by addressing significant unmet medical needs in these viral infections. The company is positioned to capitalize on a growing market, particularly with the rising incidence of untreated HCV cases, marking it as a key player in the broader viral therapy landscape.

Bull says

  • ↑Phase III C-BEYOND trial showed 93.9% SVR, non-inferior to standards.
  • ↑Cash position of $219.5M as of June 2026 funds R&D through 2027.
  • ↑Peak US revenue potential exceeds $700M for bemnifosbuvir/ruzasvir.
  • ↑HEV candidate targets $750M–$1B market in immunocompromised patients.
  • ↑76% prescriber interest indicates strong market adoption potential.
  • ↑Moderate book-to-price ratio and low short interest hint at upside.

Bear says

  • ↓Negative earnings yield and weak profitability signal financial distress.
  • ↓Rising R&D expenses may erode cash ahead of key milestones.
  • ↓Competition from Gilead, AbbVie, and Merck could limit regimen uptake.
  • ↓Regulatory delays or negative C-Forward results risk NDA timing.
  • ↓Market skepticism toward new HCV entrants may hinder adoption.
  • ↓Small size and poor balance sheet quality raise funding concerns.

Investment themes with AVIR

Buybacks↓ -0.29%

Companies repurchasing their own shares

C · JCI · WFC

Earnings Call · Q2 2025 · Mgmt. Guidance

Updated 08-16-2026bullish

Transcript signals

Bull points

  • In April, we announced the repurchase of up to $25 million of the company's common stock. This initiative reflects the company's commitment to return capital to shareholders, while maintaining the capacity to complete its global Phase III HCV program and to position ATEA for long-term success.
  • As of June 30th, we had repurchased and retired 4.6 million shares of ATEA common stock.
  • For the second quarter, we made important progress in our HCV program, evaluating the potential best-in-class regimen of Benifazi and Roosevelt.

Bear points

  • Interest income in Q2 2025 was lower than the second quarter of 2024, due to lower investment balances.
  • the study showed that BEM-RZR would be used in approximately half their patients.
Read full transcript analysis ›